Die folgenden Links führen aus den jeweiligen lokalen Bibliotheken zum Volltext:
Alternativ können Sie versuchen, selbst über Ihren lokalen Bibliothekskatalog auf das gewünschte Dokument zuzugreifen.
Bei Zugriffsproblemen kontaktieren Sie uns gern.
15 Ergebnisse
Sortierung:
In: Human development, Band 23, Heft 3, S. 192-209
ISSN: 1423-0054
In: The journal of psychology: interdisciplinary and applied, Band 85, Heft 2, S. 235-244
ISSN: 1940-1019
In: Human development, Band 14, Heft 1, S. 71-80
ISSN: 1423-0054
In: The American journal of sociology, Band 59, Heft 6, S. 565-574
ISSN: 1537-5390
In: Socio-economic planning sciences: the international journal of public sector decision-making, Band 21, Heft 3, S. 159-165
ISSN: 0038-0121
In: Sociological inquiry: the quarterly journal of the International Sociology Honor Society, Band 32, Heft 1, S. 128-135
ISSN: 1475-682X
In: The American journal of sociology, Band 61, Heft 5, S. 404-412
ISSN: 1537-5390
In: Administration, Band 39, Heft 4, S. 310
ISSN: 0001-8325
In: Exchange: The Organizational Behavior Teaching Journal, Band 3, Heft 4, S. 45-47
In: MSU Series on Children, Youth and Families Ser. v.5
Introduction / John C. McKinney and Edgar T. Thompson -- Continuity and change in sociological perspective / John C. McKinney -- The changing regional character of the south / H.H. Winsborough -- Continuity and change in southern migration / C. Horace Hamilton -- Urbanization in the south / Leonard Reissman -- Southern economic trends and prospects / Joseph J. Spengler -- Trends in southern money, income, savings, and investment / Joe S. Floyd -- Transportation and communication / Daniel O. Fletcher -- Technological change and the social order / E. William Noland -- The changing occupational structure of the south / Richard L. Simpson and David R. Norsworthy -- Change and resistance to change in the southern labor movement / Donald F. Roy -- Southern agriculture in a commercial era / C.E. Bishop -- Education and the new south / Solon T. Kimball -- The role of higher education in the changing south / Allan M. Cartter --
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ebiom.2016.05.006 ; Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. A high percentage of isoniazid resistance is linked to mutations in the pro-drug activating enzyme KatG, so the discovery of direct inhibitors (DI) of the enoyl-ACP reductase (InhA) has been pursued by many groups leading to the identification of different enzyme inhibitors, active against Mycobacterium tuberculosis (Mtb), but with poor physicochemical properties to be considered as preclinical candidates. Here, we present a series of InhA DI active against multidrug (MDR) and extensively (XDR) drug-resistant clinical isolates as well as in TB murine models when orally dosed that can be a promising foundation for a future treatment. ; The research leading to these results has received funding from GlaxoSmithKline R&D the Global Alliance for TB Drug Development, and from the European Union's 7th framework program (FP7-2007-2013) under the Orchid grant agreement no. 261378 ; Sí
BASE
Altres ajuts: The research leading to these results has received funding fromGlaxoSmithKline R&D the Global Alliance for TB Drug Development, and from the European Union's 7th framework program (FP7-2007-2013) under the Orchid grant agreement no.261378. ; Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. A high percentage of isoniazid resistance is linked to mutations in the pro-drug activating enzyme KatG, so the discovery of direct inhibitors (DI) of the enoyl-ACP reductase (InhA) has been pursued by many groups leading to the identification of different enzyme inhibitors, active against Mycobacterium tuberculosis (Mtb), but with poor physicochemical properties to be considered as preclinical candidates. Here, we present a series of InhA DI active against multidrug (MDR) and extensively (XDR) drug-resistant clinical isolates as well as in TB murine models when orally dosed that can be a promising foundation for a future treatment. Last year, Mycobacterium tuberculosis had the doubtful honor of being the top infectious killer worldwide. The current 6-month treatment, which was developed more than 30 years ago, has saved million of lives but bears the drawback of poor compliance; hence, the world needs a new shorter and safer TB treatment. The biochemical screening of GSK compound library performed by Martinez et al. has identified new KatG-independent inhibitor of InhA active against M(X)DR Mtb strains, good drug-like properties, and in vivo activity similar to isoniazid overcoming the resistance and toxicological issues of the former drug.
BASE